

## Special Issue

# From Bench to Bedside: Translational Breakthroughs in Castration-Resistant Prostate Cancer Research

### Message from the Guest Editor

Prostate cancer is the second most diagnosed malignancy and the fifth leading cause of cancer death among men globally, underscoring the urgent need for advanced therapeutic strategies. This Special Issue will present cutting-edge translational research that bridges experimental science and clinical application, focusing on the persistent challenge of CRPC. Contributions should detail the progress in this field, from identifying molecular targets in the lab to developing novel therapies that enhance patients' quality of life and survival. We welcome submissions detailing innovative diagnostic approaches, targeted therapies, immunotherapies, antibody–drug conjugates (ADCs), and strategies for overcoming drug resistance. Researchers are invited to share their findings on the biology of CRPC, particularly new insights into its development and progression, and the translation of these findings into clinical practice. This Special Issue aims to be a testament to the collaborative efforts of scientists and clinicians who are turning the tide against prostate cancer, offering hope through their commitment to research that culminates in saving lives.

### Guest Editor

Dr. Wanting Han

Pete Nelson Lab, Human Biology, Fred Hutchinson Cancer Center,  
Seattle, WA, USA

### Deadline for manuscript submissions

closed (31 December 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/191422](https://mdpi.com/si/191422)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).